NYSE:ENZ - Enzo Biochem Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.55 +0.07 (+1.08 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$6.48
Today's Range$6.50 - $6.59
52-Week Range$5.35 - $12.04
Volume57,100 shs
Average Volume179,640 shs
Market Capitalization$304.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem logoEnzo Biochem, Inc., an integrated diagnostic bioscience company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 29 patient service centers in New York and New Jersey; and a free standing ?STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ENZ
CUSIPN/A
Phone212-583-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.51
Quick Ratio4.13

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$107.80 million
Price / Sales2.85
Cash Flow$0.0237 per share
Price / Cash276.91
Book Value$1.91 per share
Price / Book3.43

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-2,500,000.00
Net Margins-1.38%
Return on Equity-2.95%
Return on Assets-2.42%

Miscellaneous

Employees472
Outstanding Shares46,930,000

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) announced its quarterly earnings results on Monday, March, 12th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.03. The medical research company had revenue of $26.95 million for the quarter, compared to the consensus estimate of $27.35 million. Enzo Biochem had a negative return on equity of 2.95% and a negative net margin of 1.38%. View Enzo Biochem's Earnings History.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani Ph.D., Co-Founder, Chairman, CEO & Sec. (Age 75)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 68)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 52)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 60)
  • Dr. Dieter Schapfel, Chief Medical Director (Age 55)

Has Enzo Biochem been receiving favorable news coverage?

Headlines about ENZ stock have been trending somewhat positive on Monday, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzo Biochem earned a coverage optimism score of 0.09 on Accern's scale. They also gave headlines about the medical research company an impact score of 46.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Evermore Global Advisors LLC (10.22%), BlackRock Inc. (7.84%), Dimensional Fund Advisors LP (4.30%), Millennium Management LLC (1.12%), Northern Trust Corp (1.09%) and ClariVest Asset Management LLC (0.86%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Which institutional investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including O Shaughnessy Asset Management LLC, Allianz Asset Management GmbH, ClariVest Asset Management LLC, Dimensional Fund Advisors LP, Prudential Financial Inc., State Board of Administration of Florida Retirement System, Russell Investments Group Ltd. and Wells Fargo & Company MN. Company insiders that have sold Enzo Biochem company stock in the last year include Barry W Weiner, Elazar Rabbani, Gregory M Bortz and James Michael O'brien. View Insider Buying and Selling for Enzo Biochem.

Which institutional investors are buying Enzo Biochem stock?

ENZ stock was purchased by a variety of institutional investors in the last quarter, including Evermore Global Advisors LLC, Millennium Management LLC, Algert Global LLC, JPMorgan Chase & Co., Alambic Investment Management L.P., Marathon Capital Management, Citadel Advisors LLC and Wedge Capital Management L L P NC. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $6.55.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $304.08 million and generates $107.80 million in revenue each year. Enzo Biochem employs 472 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave, New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.


MarketBeat Community Rating for Enzo Biochem (ENZ)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzo Biochem (NYSE:ENZ) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/21/2016 forward)

Earnings

Enzo Biochem (NYSE:ENZ) Earnings History and Estimates Chart

Earnings by Quarter for Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE ENZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q2 2018($0.01)($0.04)$27.35 million$26.95 millionViewListenView Earnings Details
12/7/2017Q1 2018($0.01)($0.01)$27.51 million$27.68 millionViewListenView Earnings Details
3/13/2017Q2 2017($0.04)($0.02)$26.10 million$26.26 millionViewN/AView Earnings Details
12/8/2016Q117($0.05)($0.03)$25.90 million$26.28 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.00 million$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.00 million$25.18 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 million$23.99 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$24.20 million$23.09 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 million$24.82 millionViewListenView Earnings Details
10/9/2014Q4 2014($0.07)($0.06)$23.60 million$24.91 millionViewListenView Earnings Details
6/9/2014Q314($0.09)($0.05)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)$24.13 millionViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
3/12/2013Q2 2013($0.06)($0.14)$25.02 million$22.21 millionViewN/AView Earnings Details
12/10/2012Q1 2013($0.06)($0.09)ViewN/AView Earnings Details
10/15/2012Q4 2012($0.07)($0.11)ViewN/AView Earnings Details
6/11/2012Q3 2012($0.07)($0.09)ViewN/AView Earnings Details
3/12/2012Q2 2012($0.09)($0.11)ViewN/AView Earnings Details
12/12/2011Q1 2012($0.07)($0.12)ViewN/AView Earnings Details
10/14/2011Q4 2011($0.09)($0.11)ViewN/AView Earnings Details
6/9/2011Q3 2011($0.10)($0.05)ViewN/AView Earnings Details
3/14/2011Q2 2011($0.10)($0.15)ViewN/AView Earnings Details
12/13/2010Q1 2011($0.08)($0.03)ViewN/AView Earnings Details
10/14/2010Q4 2010($0.10)($0.10)ViewN/AView Earnings Details
6/9/2010Q3 2010($0.08)($0.12)ViewN/AView Earnings Details
3/12/2010Q2 2010($0.08)($0.27)ViewN/AView Earnings Details
12/10/2009Q1 2010($0.10)($0.05)ViewN/AView Earnings Details
10/14/2009Q4 2009($0.05)($0.14)ViewN/AView Earnings Details
6/15/2009Q3 2009($0.08)ViewN/AView Earnings Details
3/12/2009Q2 2009($0.21)ViewN/AView Earnings Details
12/10/2008Q1 2009($0.04)($0.17)ViewN/AView Earnings Details
10/14/2008Q4 2008($0.06)($0.09)ViewN/AView Earnings Details
6/9/2008Q3 2008($0.07)($0.06)ViewN/AView Earnings Details
3/11/2008Q2 2008($0.12)($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Enzo Biochem (NYSE:ENZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Enzo Biochem (NYSE ENZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.90%
Institutional Ownership Percentage: 67.04%
Insider Trading History for Enzo Biochem (NYSE:ENZ)
Insider Trading History for Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE ENZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2018Barry W WeinerCFOSell11,000$7.75$85,250.001,313,111View SEC Filing  
1/17/2018Elazar RabbaniCEOSell14,000$7.75$108,500.001,867,202View SEC Filing  
10/31/2017Gregory M BortzDirectorSell42,005$9.82$412,489.10292,875View SEC Filing  
10/27/2017James Michael O'brienEVPSell22,866$10.28$235,062.4834,886View SEC Filing  
10/25/2017Barry W WeinerCFOSell54,126$10.11$547,213.861,423,367View SEC Filing  
10/25/2017Elazar RabbaniCEOSell72,401$10.09$730,526.092,038,474View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enzo Biochem (NYSE ENZ) News Headlines

Source:
DateHeadline
Fulgent Genetics (FLGT) and Enzo Biochem (ENZ) Head-To-Head ReviewFulgent Genetics (FLGT) and Enzo Biochem (ENZ) Head-To-Head Review
www.americanbankingnews.com - May 20 at 1:39 PM
Head to Head Comparison: Cancer Genetics (CGIX) & Enzo Biochem (ENZ)Head to Head Comparison: Cancer Genetics (CGIX) & Enzo Biochem (ENZ)
www.americanbankingnews.com - May 4 at 3:22 AM
Head to Head Contrast: Enzo Biochem (ENZ) & OpGen (OPGN)Head to Head Contrast: Enzo Biochem (ENZ) & OpGen (OPGN)
www.americanbankingnews.com - April 24 at 7:58 PM
Head-To-Head Analysis: Enzo Biochem (ENZ) & Genomic Health (GHDX)Head-To-Head Analysis: Enzo Biochem (ENZ) & Genomic Health (GHDX)
www.americanbankingnews.com - April 24 at 5:16 PM
Health Care Sector Update for 04/24/2018: ENZ,HOLX,BIIB,CNC,INCYHealth Care Sector Update for 04/24/2018: ENZ,HOLX,BIIB,CNC,INCY
www.nasdaq.com - April 24 at 4:17 PM
Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement ...Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement ...
www.businesswire.com - April 24 at 4:17 PM
BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes ...BRIEF-Enzo Biochem Says Patent Trial And Appeal Board Has Denied A Petition Filed By Hologic For Inter Partes ...
www.reuters.com - April 24 at 4:17 PM
Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement CasePatent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement Case
finance.yahoo.com - April 24 at 4:17 PM
Report: Exploring Fundamental Drivers Behind Enzo Biochem, The Hackett Group, Rexford Industrial Realty, Green ...Report: Exploring Fundamental Drivers Behind Enzo Biochem, The Hackett Group, Rexford Industrial Realty, Green ...
globenewswire.com - April 24 at 9:50 AM
Notable Monday Option Activity: BA, ENZ, WDCNotable Monday Option Activity: BA, ENZ, WDC
www.nasdaq.com - April 24 at 9:50 AM
Enzo Biochem (ENZ) Upgraded to Strong-Buy by BidaskClubEnzo Biochem (ENZ) Upgraded to Strong-Buy by BidaskClub
www.americanbankingnews.com - April 17 at 3:39 PM
Head-To-Head Review: Enzo Biochem (ENZ) versus Its PeersHead-To-Head Review: Enzo Biochem (ENZ) versus Its Peers
www.americanbankingnews.com - April 17 at 3:13 AM
Financial Comparison: Enzo Biochem (ENZ) vs. Its CompetitorsFinancial Comparison: Enzo Biochem (ENZ) vs. Its Competitors
www.americanbankingnews.com - April 15 at 5:15 PM
Enzo Biochem (ENZ) versus Its Peers Critical ReviewEnzo Biochem (ENZ) versus Its Peers Critical Review
www.americanbankingnews.com - April 14 at 3:17 AM
Enzo Biochem (ENZ) Rating Lowered to Hold at BidaskClubEnzo Biochem (ENZ) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 12 at 6:46 PM
Critical Comparison: Enzo Biochem (ENZ) & The CompetitionCritical Comparison: Enzo Biochem (ENZ) & The Competition
www.americanbankingnews.com - April 11 at 11:21 AM
Enzo Biochem (ENZ) Stock Rating Lowered by BidaskClubEnzo Biochem (ENZ) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 6:07 PM
Contrasting Enzo Biochem (ENZ) & Its CompetitorsContrasting Enzo Biochem (ENZ) & Its Competitors
www.americanbankingnews.com - April 9 at 7:21 PM
Reviewing Enzo Biochem (ENZ) and Biocept (BIOC)Reviewing Enzo Biochem (ENZ) and Biocept (BIOC)
www.americanbankingnews.com - April 2 at 7:16 PM
Head-To-Head Comparison: Enzo Biochem (ENZ) versus Its CompetitorsHead-To-Head Comparison: Enzo Biochem (ENZ) versus Its Competitors
www.americanbankingnews.com - March 19 at 5:16 PM
Edited Transcript of ENZ earnings conference call or presentation 13-Mar-18 12:30pm GMTEdited Transcript of ENZ earnings conference call or presentation 13-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 9:50 AM
Enzo Biochem (ENZ) Q2 2018 Results - Earnings Call Transcript - Seeking AlphaEnzo Biochem (ENZ) Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 11:06 AM
Earnings Outlook For Enzo Biochem - BenzingaEarnings Outlook For Enzo Biochem - Benzinga
www.benzinga.com - March 14 at 11:06 AM
Earnings Outlook For Enzo BiochemEarnings Outlook For Enzo Biochem
finance.yahoo.com - March 13 at 5:54 PM
Enzo Biochem (ENZ) Posts Quarterly  Earnings Results, Misses Estimates By $0.03 EPSEnzo Biochem (ENZ) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - March 13 at 10:38 AM
Enzo Biochem Reports Second Quarter and First Half ResultsEnzo Biochem Reports Second Quarter and First Half Results
finance.yahoo.com - March 12 at 5:03 PM
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 at 8:30 AM E.T.Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 at 8:30 AM E.T.
finance.yahoo.com - March 8 at 4:47 PM
Millrace Asset Group Inc. Has $1.39 Million Holdings in Enzo Biochem, Inc. (ENZ)Millrace Asset Group Inc. Has $1.39 Million Holdings in Enzo Biochem, Inc. (ENZ)
www.americanbankingnews.com - March 5 at 12:54 PM
Enzo Biochem (ENZ) Downgraded by ValuEngine to "Sell"Enzo Biochem (ENZ) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 4 at 7:16 PM
Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection TestEnzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test
finance.yahoo.com - January 30 at 9:08 AM
Insider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 11,000 Shares of StockInsider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 11,000 Shares of Stock
www.americanbankingnews.com - January 19 at 10:26 PM
Enzo Biochem, Inc. (ENZ) CEO Elazar Rabbani Sells 14,000 SharesEnzo Biochem, Inc. (ENZ) CEO Elazar Rabbani Sells 14,000 Shares
www.americanbankingnews.com - January 19 at 10:26 PM
Free Post Earnings Research Report: Enzo Biochem’s Revenue Grew 5%; Net Loss NarrowedFree Post Earnings Research Report: Enzo Biochem’s Revenue Grew 5%; Net Loss Narrowed
finance.yahoo.com - January 9 at 9:23 AM
Noteworthy Friday Option Activity: CSX, GLPI, ENZNoteworthy Friday Option Activity: CSX, GLPI, ENZ
www.nasdaq.com - December 15 at 6:04 PM
Blog Exposure - Cancer Genetics Announces Best Diagnostic Modality to Evaluate PD-L1 in Diffuse Large B-Cell LymphomasBlog Exposure - Cancer Genetics Announces Best Diagnostic Modality to Evaluate PD-L1 in Diffuse Large B-Cell Lymphomas
finance.yahoo.com - December 13 at 9:35 AM
Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q1, 2018 By the Numbers : December 11, 2017Enzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q1, 2018 By the Numbers : December 11, 2017
finance.yahoo.com - December 11 at 5:41 PM
Enzo Biochem (ENZ) Q1 2018 Earnings Conference Call TranscriptEnzo Biochem (ENZ) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - December 11 at 5:41 PM
Edited Transcript of ENZ earnings conference call or presentation 8-Dec-17 1:30pm GMTEdited Transcript of ENZ earnings conference call or presentation 8-Dec-17 1:30pm GMT
finance.yahoo.com - December 9 at 9:24 AM
Enzo Biochem (ENZ) Releases Quarterly  Earnings Results, Hits EstimatesEnzo Biochem (ENZ) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - December 8 at 9:24 AM
Enzo Biochem, Inc. to Host Earnings CallEnzo Biochem, Inc. to Host Earnings Call
finance.yahoo.com - December 8 at 9:18 AM
ETFs with exposure to Enzo Biochem, Inc. : December 7, 2017ETFs with exposure to Enzo Biochem, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem reports 1Q lossEnzo Biochem reports 1Q loss
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem Reports Improved First Quarter ResultsEnzo Biochem Reports Improved First Quarter Results
finance.yahoo.com - December 7 at 5:57 PM
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.
finance.yahoo.com - December 5 at 10:01 AM
Global Healthcare Biomarkers Market Size will Exceed US$ 56 Billion By 2022Global Healthcare Biomarkers Market Size will Exceed US$ 56 Billion By 2022
www.marketwatch.com - November 16 at 1:55 PM
Enzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 SharesEnzo Biochem, Inc. (ENZ) Director Gregory M. Bortz Sells 42,005 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
James Michael Obrien Sells 22,866 Shares of Enzo Biochem, Inc. (ENZ) StockJames Michael O'brien Sells 22,866 Shares of Enzo Biochem, Inc. (ENZ) Stock
www.americanbankingnews.com - October 30 at 11:28 PM
Insider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 54,126 Shares of StockInsider Selling: Enzo Biochem, Inc. (ENZ) CFO Sells 54,126 Shares of Stock
www.americanbankingnews.com - October 27 at 8:40 PM
Insider Selling: Enzo Biochem, Inc. (ENZ) CEO Sells 72,401 Shares of StockInsider Selling: Enzo Biochem, Inc. (ENZ) CEO Sells 72,401 Shares of Stock
www.americanbankingnews.com - October 27 at 8:40 PM
ETFs with exposure to Enzo Biochem, Inc. : October 24, 2017ETFs with exposure to Enzo Biochem, Inc. : October 24, 2017
finance.yahoo.com - October 24 at 10:08 PM

SEC Filings

Enzo Biochem (NYSE:ENZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enzo Biochem (NYSE:ENZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzo Biochem (NYSE ENZ) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.